Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The EC has approved GSK's Jemperli (dostarlimab) combined with chemotherapy for primary advanced or recurrent endometrial ...

The safety and tolerability analysis from RUBY Part 1 showed a safety profile for Jemperli ... Recently, GSK agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Vortex Biotech Holdings, (‘Vortex’, or ‘the Company’), a leading oncology liquid biopsy company, is pleased to announce the appointment of Nigel Brooksby as Non-Executive Chairman. Nigel is an ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The investment seeks to provide investment results that correspond generally, before fees and expenses, to the total return of the ordinary shares of GSK plc in its local market. The series, under ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...